DRIO: New Client Wins And Pricing Initiatives Will Drive Upside Potential

Analysts have lowered their price target for DarioHealth from $22.25 to $19.75, citing concerns about slower revenue growth and a weaker profit margin. Some anticipate potential recovery if the company's strong pipeline delivers in coming years.

Analysts have reiterated their target price for DarioHealth at $22.25 per share. They are maintaining their outlook based on updated assumptions regarding discount rates and profit margins.

Narrative Update: DarioHealth Analysts have maintained their price target for DarioHealth at $22.25, citing stable growth projections and recent adjustments to key financial metrics. What's in the News DarioHealth announced the addition of six new employer clients, expanding its value-based care strategy by implementing a pricing model tied to member engagement and clinical outcomes (Client Announcements).

DarioHealth's analyst price target has been revised downward from $25.50 to $22.25. This reflects analysts' updated outlook based on lower fair value estimates and a slightly reduced discount rate.

DarioHealth’s fair value estimate has been reduced, driven by a substantial drop in future P/E and a higher discount rate, resulting in the analyst price target falling from $39.25 to $25.50. What's in the News Launched five new contracts with self-insured employers for Dario’s full cardiometabolic suite, demonstrating improvements in diabetes (1.4% eHbA1c reduction), prediabetes (10% BMI reduction), and hypertension (38% users lowered stage).

DarioHealth’s fair value assessment has increased markedly due to a substantial drop in future P/E, outweighing a minor rise in the discount rate, resulting in the consensus analyst price target jumping from $1.96 to $39.25. What's in the News DarioHealth announced a 1-for-20 reverse stock split to be implemented as determined by the Board no later than September 15, 2025.

With both the discount rate and revenue growth forecasts holding steady, analyst valuation for DarioHealth remained unchanged, with the consensus price target steady at $1.96. What's in the News Shareholders ratified the appointment of Kesselman & Kesselman (PwC) as independent auditor for 2025.